论文部分内容阅读
2004年新年伊始,德国先灵公司执行董事会成员Stock教授一行访华。Stock教授针对该公司在抗肿瘤药物研发方面的创新理念,以及两个计划进入中国市场的抗肿瘤新药MabCampath和Zevalin进行了通报。做为特约嘉宾,北京协和医院内科主任兼血液科主任沈悌教授做了主题演讲。 Stock教授:先灵公司在肿瘤学研发中的进展 开发出了应用于前列腺治疗的针对雄激素受体的抗激素治疗药物。随着CT尤其是MRI对比剂的
At the beginning of the new year 2004, Stock Professor Debenhammedt, executive chairman of Germany's Schering Company, paid a visit to China. Professor Stock directed the company's innovative ideas in the development of anticancer drugs, as well as two anti-tumor drugs MabCampath and Zevalin, planned to enter the Chinese market. As a special guest, Peking Union Medical College Hospital Director of Hematology and Professor Shen Jie made a keynote speech. Stock Professor: Schering Corporation Advances in Oncology Research and Development The anti-hormone therapy for androgen receptor has been developed for prostate treatment. With CT especially MRI contrast agent